Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb